+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 236 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
O

Actively Recruiting

Researchers are investigating new treatment options for people with precursor B-cell Acute Lymphoblastic Leukemia B-ALL that has either returned after treatment relapsed or stopped responding to current therapies refractory. This study has two parts the first part focuses on finding the safest and most effective dose of the study drug MK-1045, while the second part aims to understand how well MK-1045 works to treat B-ALL. Participants receive MK-1045 through an intravenous infusion once a week. Adults in the dose escalation phase will be given doses ranging from 600 micrograms to 120,000 micrograms, while pediatric participants receive doses from 320 micrograms to 60,000 micrograms, adjusted based on their weight. Treatment cycles last 4 weeks, starting with two cycles of induction therapy, followed by consolidation and maintenance treatments separated by breaks depending on response and tolerance. During the study, researchers monitor participants closely with various tests to assess safety, drug levels in the blood, immune cell changes, and treatment responses. These include tracking adverse events, remission rates, and survival outcomes over time. The study involves up to 24 months of follow-up to evaluate both the safety and effectiveness of MK-1045 in treating relapsed or refractory B-ALL.

Age: 2Years +All GendersPhase 1Phase 2
11 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Recombinant Botulinum Toxin Type A YY001 injections for treating upper limb spasticity in adults who have had a stroke. This randomized, double-blind, multi-center phase IIIII study compares YY001 with BOTOX4 and a placebo to better understand treatment options for this condition. Participants will receive a single intramuscular injection of either Recombinant Botulinum Toxin Type A YY001 with a dose of 200-400 units, BOTOX4 with a dose of 200 units, or a placebo prepared with saline. The study includes three groups the experimental group receiving YY001, an active-controlled group receiving BOTOX4, and a placebo-controlled group. Each participant receives only one injection during the treatment period. During the study, participants will be monitored at 1, 4, 8, and 12 weeks after treatment through assessments such as the Modified Ashworth Scale MAS for spasticity, Physicians Global Assessment, and Disability Assessment Scale DAS. Researchers will also track any adverse events and the presence of antibodies to the treatment. The primary outcome is the change in MAS score at week 4. The study lasts at least 12 weeks with ongoing safety and efficacy follow-up.

Age: 18Years - 75YearsAll GendersPhase 2Phase 3
24 locations
E

Actively Recruiting

Researchers are evaluating the LVIVO-TaVec200 product in a dose-escalation and dose-expansion clinical study for adults with relapsed or refractory multiple myeloma who have not responded to at least three prior standard treatments. This early phase 1 study aims to assess the safety, tolerability, anti-tumor effects, and how the product behaves in the body over time. The study is open-label and single-arm, focusing on this specific patient group with measurable disease and a reasonable life expectancy. Participants will receive a single infusion of the LVIVO-TaVec200 product at increasing dose levels. Before the infusion, some participants may receive bridging therapy if needed. The study includes a core period lasting about two years, which covers screening, bridging therapy, treatment, and follow-up phases. Researchers will monitor patients closely throughout this time to determine the recommended dose for future studies. During the study, participants will undergo various assessments, including monitoring for treatment-emergent adverse events, and testing the pharmacokinetics of the product in peripheral blood and bone marrow. These evaluations will continue through the two-year follow-up period after infusion. Participants will be regularly assessed for safety and treatment effects, with ongoing follow-up to track their response and health status throughout the study duration.

Age: 18Years +All GendersEarly Phase 1
5 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.

Age: 18Years +All GendersPhase 3
210 locations
S

Actively Recruiting

This research aims to study the safety and tolerability of B019 injection in individuals diagnosed with relapsed or refractory B-cell acute lymphoblastic leukemia, a type of blood cancer. The trial focuses on patients between 3 and 25 years old who have experienced a return or resistance to previous treatments. The study is sponsored by Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. and is designed as a Phase 1 interventional trial to evaluate preliminary effects and safety. Participants will receive B019, a biological treatment given as an intravenous infusion of CAR T cells, with doses ranging from 1.0 106 to 10.0 106 CAR T cells per kilogram of body weight. This study uses a single-group design, meaning all participants receive the B019 infusion. The study includes a treatment phase and will continue monitoring for approximately two years to assess safety and treatment responses. During the trial, participants will be closely monitored for treatment-related adverse events for about two years. Researchers will also evaluate overall response to treatment within three months and overall survival during the two-year period. Pharmacokinetic measures such as Tmax and Cmax will be tracked to understand how the treatment behaves in the body. Participants will undergo regular assessments including laboratory tests and clinical evaluations to ensure safety and measure treatment effects throughout the study duration.

Age: 3Years - 25YearsAll GendersPhase 1
8 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics PK, and immune response of a drug called SV001 in patients with idiopathic pulmonary fibrosis IPF, a lung condition. This Phase IIa clinical trial is randomized, double-blind, and placebo-controlled, aiming to gather detailed information about how the drug behaves in the body and its safety profile. Participants will receive multiple doses of SV001 or a placebo, with the study designed to compare these groups. The treatment period includes escalating doses to assess how the drug is tolerated and processed by the body. The study will last approximately one year, during which participants will be closely monitored. During the trial, participants will undergo regular assessments including checking for treatment-related adverse events, measuring the drug concentration in blood over time, and testing for immune responses. The main outcome is the incidence of adverse events over about one year. Additional evaluations will look at peak drug levels, time to peak levels, drug exposure over time, half-life, and immunogenicity. Safety and tolerability will be continuously monitored throughout the study period.

Age: 40Years +All GendersPhase 2
12 locations
E

Actively Recruiting

Researchers are evaluating the combination of BNT324, a B7-H3 antibody-drug conjugate, with BNT327, a bispecific antibody targeting PD-L1 and VEGF, in adults with advanced or metastatic small cell lung cancer SCLC and non-small cell lung cancer NSCLC. This two-part Phase IbII trial aims to find safe dose levels, optimize dosing, and assess preliminary efficacy and safety in various lung cancer patient groups. Participants in Part 1 receive escalating doses of BNT324 with BNT327 to determine recommended dose levels. Part 2 compares these dose levels in randomized cohorts of treatment-naive NSCLC and relapsed SCLC patients, with additional cohorts receiving the optimal dose to further evaluate efficacy and safety. Treatments are given via intravenous infusion, and dosing is adjusted based on safety and response data. Throughout the study, participants undergo screening, treatment, safety follow-up, and long-term survival monitoring. Researchers assess dose-limiting toxicities, adverse events, objective response rates, disease control, progression-free survival, and overall survival. Treatment effects are evaluated up to 87 months, with close monitoring for side effects and treatment tolerability during and after therapy.

Age: 18Years +All GendersPhase 1Phase 2
91 locations
S

Actively Recruiting

Researchers are evaluating if ifinatamab deruxtecan I-DXd, an antibody-drug conjugate, can treat people with advanced esophageal squamous cell carcinoma ESCC who have not responded to previous treatments. The study aims to find out how many participants experience cancer shrinkage or disappearance after receiving I-DXd. This trial is a phase 2, open-label study focusing on participants with unresectable locally advanced or metastatic ESCC. Participants receive I-DXd through an intravenous infusion every 3 weeks. Treatment continues until the cancer progresses or other discontinuation criteria are met. The study includes a single group where all participants receive I-DXd. Rescue medications such as 5-HT3 receptor antagonists, NK-1 receptor antagonists, and corticosteroids may be given as needed according to approved guidelines. Throughout the study, participants are regularly monitored for tumor response, side effects, and overall health. Researchers assess the objective response rate up to about 14 months, as well as secondary outcomes including duration of response, progression-free survival, overall survival, and adverse events. The total study duration spans up to approximately 26 months, allowing for ongoing safety evaluations and follow-up.

Age: 18Years +All GendersPhase 1Phase 2
32 locations
T

Actively Recruiting

Researchers are investigating a combination therapy of BNT326 and pumitamig for adults with advanced or metastatic non-small cell lung cancer NSCLC that has either relapsed, progressed, or is treatment-nafve. The study includes multiple parts to find the best dose levels, assess safety and tolerability, and evaluate how well the therapy works to shrink tumors in this patient population. The trial is open-label and conducted across multiple sites, focusing on participants with confirmed advanced NSCLC where no curative treatment is available. The study consists of three parts Part 1 focuses on finding safe dose combinations of BNT326 with pumitamig Part 2a expands the dose evaluation to examine preliminary effectiveness and safety and Part 2b randomizes participants to optimize dosing and assess the contribution of each therapy component. Participants with prior treatment and those who are treatment-nafve are enrolled in different cohorts. Treatment is administered via intravenous infusion, and dose levels for Part 2b are determined based on earlier results. Participants undergo a screening period before starting treatment, which can continue for up to 24 months or until disease progression or unacceptable side effects occur. Follow-up periods monitor safety, efficacy, and long-term survival, with total involvement expected to last about 36 months unless ongoing benefit warrants extended treatment. Researchers evaluate dose-limiting toxicities, adverse events, tumor response rates, progression-free survival, and pharmacokinetics to understand treatment effects and participant outcomes.

Age: 18Years +All GendersPhase 1Phase 2
86 locations

1-10 of 236

1